Bextral Competitors

At IBM, we do more than work. We create. We create as technologists, developers, and engineers. We create with our partners. We create with our competitors. If you're searching for ways to make the world work better through technology and infrastructure, software and consulting, then we want to work with you. We're here to help every creator turn their "what if" into what is. Let's create something that will change everything.

Empowering People to Take Control of Health Dexcom Corporation (NASDAQ DXCM) has been a pioneer in glucose sensing for more than 25 years. Since 1999, we have developed innovative technologies that transformed how people manage diabetes. Our products are part of people’s daily lives, empowering them to live confidently and feel more in control, free to pursue their dreams. Headquartered in San Diego, California, with operations around the world, Dexcom leads by listening to the needs of users, caregivers, and providers, to simplify and improve glucose management.

For 15 years, Omada Health has been in the corner of millions of Americans managing chronic conditions. We help our members between doctor visits, providing virtual care that adapts to real life. We partner with employers, health plans, pharmacy benefit managers, and government agencies to support their populations across common chronic conditions — from prediabetes, diabetes, and hypertension to muscle and joint pain— all through the convenience of an app. Our programs also adapt to provide specialized care for GLP-1 journeys. At Omada, care isn’t built for perfection. It’s built for real people. Our clinically-validated programs combine human connection with modern technology, pairing members with real coaches and care teams. Omada’s impact is proven: our outcomes are published in 30 peer-reviewed studies, showing lasting behavior change, reduced healthcare costs, and ROI for our partners. Our success starts with our people. Omada’s strong, inclusive culture has earned us the Great Place to Work certification, and in 2025 we became a Nasdaq-listed company — a milestone on our mission to bend the curve of chronic disease.